Creating synergies and expanding into new areas through reorganization and integration within the healthcare business
First written in FY2018-Q4. 12 of 22 entries say "Advanced", first in FY2019-Q1. Latest entry: 2026-08-07.
4 other companies' latest entry also says "Advanced".
- FY2026-H1ReframedAnnual report
「In the marketing support (healthcare) business, the company will expand into new areas such as promotion and communications to become a decision-making partner in healthcare, while pursuing initiatives to create new value from a Patient Centricity perspective. It will also accelerate efforts to improve operational efficiency and exceed customer expectations by leveraging AI and group assets.」
The Healthcare business's decision-making partner policy now also covers expansion into promotion and communications, creation of value based on Patient Centricity, and operational efficiency through the use of AI and group assets. - FY2025AdvancedAnnual report
「The marketing support (healthcare) business reported a ¥12,432 million decrease in revenue, down 13.3% year on year, and operating income of ¥2,133 million, up 25.7%, resulting in lower revenue but higher profit. Revenue declined due to the sale of the CRO business at 株式会社インテージヘルスケア, but profitability improved substantially.」
Following the reorganization of the healthcare business, revenue declined as a result of the sale of the CRO business, while operating income increased by 25.7%, demonstrating a substantial improvement in profitability. - FY2024ReframedAnnual report
「株式会社インテージヘルスケア has refocused on its strength in “monetizing the value of data” and decided to concentrate management resources on its marketing research and data science businesses to address these challenges. Accordingly, it decided to transfer its CRO business, which supports the safety and efficacy of prescription pharmaceuticals and other products, to アルフレッサ ホールディングス株式会社, which is building an integrated total supply chain service covering pharmaceuticals from development through manufacturing, sales, distribution and PMS.」
The direction of the healthcare business was reorganized from leveraging assets through integration and expanding into new areas to concentrating management resources on monetizing data value and transferring the CRO business. - FY2024-Q3RestatedAnnual report
「In the marketing support (healthcare) business, to become a decision-making partner in healthcare, the company will deepen its understanding of consumers by adding healthcare consumer awareness and behavioral data to fact-based data obtained through real-world data and other sources.」
The company continues its policy of combining real-world data with healthcare consumer awareness and behavioral data to become a decision-making partner in the healthcare field. - FY2024-Q2RestatedAnnual report
「In the marketing support (healthcare) business, to become a decision-making partner in healthcare, the company will deepen its understanding of consumers by adding healthcare consumer awareness and behavioral data to fact-based data obtained through real-world data and other sources.」
The company continues its policy of combining real-world data with healthcare consumer awareness and behavioral data to become a decision-making partner in the healthcare field. - FY2024-Q1ReframedAnnual report
「In the marketing support (healthcare) business, to become a decision-making partner in healthcare, the company will deepen its understanding of consumers by adding healthcare consumer awareness and behavioral data to fact-based data obtained through real-world data and other sources. It will also develop highly specialized professionals and provide solutions that contribute to resolving customers' challenges. In addition, it will continue to strengthen its sales structure.」
The company has organized the direction of the healthcare business around becoming a decision-making partner by integrating real-world data with healthcare consumer awareness and behavioral data, rather than simply combining a broad range of businesses and assets. It continues to develop specialized personnel and strengthen its sales structure. - FY2023-Q1AdvancedAnnual report
「In the marketing support (healthcare) business, the company is strengthening healthcare real-world data, including through the renewal of its integrated database, Cross Fact, reflecting the importance of a healthcare consumer perspective. It will continue investing in the development of data science talent to provide further added value. It is also working to expand the business areas that support customers' decision-making processes.」
The company has given concrete form to the expansion of its decision-support business through the renewal of Cross Fact, the strengthening of healthcare real-world data and the development of data science talent. - FY2022AdvancedAnnual report
「In the marketing support (healthcare) business, through initiatives for transformation based on digital investment and a selective focus on priority areas since the organizational changes in 2019, the company has been building a data science-centered portfolio since the 14th Medium-Term Management Plan and aims to establish a robust earnings base.」
The company indicated a direction for transformation following the integration of the healthcare business by advancing digital investment and a selective focus on priority areas and building a data science-centered business portfolio from the 14th Medium-Term Management Plan onward. - FY2022-Q1AdvancedAnnual report
「In the marketing support (healthcare) business, the company views the growing importance of data and services relating to healthcare consumers as a growth opportunity. It is strengthening data collection with partners such as Welby and expanding the consumer domain encompassing consumption and health.」
In the healthcare business, the company is strengthening the collection of healthcare consumer data through collaboration with partners such as Welby and expanding the consumer domain by combining consumption and health. - FY2021RestatedAnnual report
「In the marketing support (healthcare) business, the company is strengthening its collaboration with Welby through a capital and business alliance. It is also pursuing expansion of its core businesses in response to changes in customer needs and the creation of new business opportunities by combining its broad range of businesses and assets, including research, data sales, post-marketing surveillance and promotion, with its understanding of consumers and patients.」
The company continues to create new business opportunities by combining the businesses and assets of the integrated healthcare operations and collaborating with Welby. - FY2021-Q3AdvancedAnnual report
「In the marketing support (healthcare) business, the company is strengthening its collaboration with Welby through a capital and business alliance. It is also pursuing expansion of its core businesses in response to changes in customer needs and the creation of new business opportunities by combining its broad range of businesses and assets, including research, data sales, post-marketing surveillance and promotion, with its understanding of consumers and patients.」
The capital and business alliance with Welby gave concrete form to collaboration in the healthcare field. The company also continues to create new business opportunities by combining the broad range of businesses and assets and its understanding of consumers and patients following the integration. - FY2021-Q2AdvancedAnnual report
「In the marketing support (healthcare) business, the company is actively collaborating with partner companies such as Welby, which provides PHR platform services specializing in treatment areas. It is also pursuing expansion of its core businesses in response to changes in customer needs and the creation of new business opportunities by combining its broad range of businesses and assets, including research, data sales, post-marketing surveillance and promotion, with its understanding of consumers and patients.」
The company is pursuing collaboration with Welby and other companies and creating new business opportunities by combining its broad range of businesses and assets in the integrated healthcare business. - FY2021-Q1RestatedAnnual report
「In the marketing support (healthcare) business, the company will expand its core businesses in response to changes in customer needs and create new business opportunities by combining its broad range of businesses and assets, including research, data sales, post-marketing surveillance and promotion, with its understanding of consumers and patients.」
The company continues its policy of creating new business opportunities in the integrated healthcare business by combining its broad range of businesses and assets with its understanding of consumers and patients. - FY2020-Q1RestatedAnnual report
「In the marketing support (healthcare) business, custom research relating to prescription pharmaceuticals and medical devices and panel surveys relating to over-the-counter drugs at 株式会社インテージヘルスケア, which was established in the current fiscal year, remained firm. However, sales are trending downward, partly due to the smaller size of commissioned post-marketing surveillance projects for CROs (contract research organizations).」
The post-integration structure, with 株式会社インテージヘルスケア at the core of the healthcare segment, has continued, with services relating to pharmaceuticals and medical devices being provided. - FY2019-Q4AdvancedAnnual report
「In the marketing support (healthcare) business, 株式会社インテージヘルスケア, established through the management integration of 株式会社アスクレップ and 株式会社アンテリオ on 1 April 2019, is positioned as the core company of the segment. The company aims to expand into new business areas by leveraging the assets and solutions held by the companies in the segment.」
The management integration of 株式会社アスクレップ and 株式会社アンテリオ was completed on 1 April 2019, and 株式会社インテージヘルスケア was established. Following the integration, the company is positioned as the core of the healthcare segment, with the aim of expanding into new areas. - FY2019-Q2RestatedAnnual report
「In the marketing support (healthcare) business, 株式会社インテージヘルスケア, the new company formed through the management integration of 株式会社アンテリオ and 株式会社アスクレップ, will be established on 1 April 2019. The purpose is to realize synergies from the integration and invest in new business areas.」
The company continues to pursue the planned establishment of 株式会社インテージヘルスケア through the management integration of 株式会社アンテリオ and 株式会社アスクレップ, together with its policy of realizing integration synergies and investing in new areas. - FY2019-Q1AdvancedAnnual report
「In June 2018, 株式会社アンテリオ made 株式会社ジュニコン, which had strengths in the medical device field and expertise in health economics analysis, a subsidiary and absorbed it in October. In September 2018, 株式会社アスクレップ made 株式会社協和企画, which operates medical promotion, education, data solutions and health technology businesses, a subsidiary.」
The absorption merger of 株式会社ジュニコン was completed and 株式会社協和企画 also became a subsidiary. In addition, plans for the management integration of 株式会社アンテリオ and 株式会社アスクレップ effective 1 April 2019 were made concrete, with healthcare-related companies to be consolidated under the integrated company. - FY2018-Q4First statedAnnual report
「The purpose of the merger is to improve management efficiency and maximize synergies in the marketing support (healthcare) business.」
The company entered into a merger agreement between 株式会社アンテリオ and 株式会社ジュニコン, explicitly disclosing for the first time a reorganization within the healthcare business, with 1 October 2018 scheduled as the merger date. In addition to improving management efficiency and maximizing synergies, the company plans to expand into the medical device market and the field of health economics analysis.